Talphera (NASDAQ:TLPH) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Talphera (NASDAQ:TLPH) in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a $6.00 price objective on the stock. HC Wainwright also issued estimates for Talphera’s Q2 2024 earnings at ($0.22) EPS, Q3 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.84) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at ($0.30) EPS and FY2028 earnings at $0.53 EPS.

Separately, Maxim Group initiated coverage on shares of Talphera in a report on Monday, May 6th. They issued a buy rating and a $3.00 target price on the stock.

Talphera Price Performance

Shares of TLPH stock opened at $1.08 on Wednesday. The business has a 50 day moving average of $1.07. Talphera has a 52 week low of $0.43 and a 52 week high of $1.61. The company has a market capitalization of $18.35 million, a price-to-earnings ratio of -1.21 and a beta of 0.46.

Talphera (NASDAQ:TLPH) last announced its earnings results on Wednesday, March 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The company had revenue of $0.28 million for the quarter. Sell-side analysts forecast that Talphera will post -0.84 EPS for the current year.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.